Dr. Berenson on the Study of Zometa in Multiple Myeloma

Video

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

Related Videos
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Changchun Deng, MD, PhD, associate professor, hematology/oncology, University Hospitals Seidman Cancer Center; member, Immune Oncology Program, Case Comprehensive Cancer Center
Jaime R. Merchán, MD
Erin Frances Cobain, MD
Mark D. Tyson, II, MD, MPH
Michael Iglesia, MD, PhD
Sundar Jagannath, MBBS
Jonathan E. Rosenberg, MD
Núria Agustí Garcia, MD
Erin Frances Cobain, MD
Related Content
HR001 in NHL | Image Credit: © Dr_Microbe - stock.adobe.com

NXC-201 Receives Orphan Drug Designation in the European Union for Multiple Myeloma

May 3rd 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Leland Metheny, MD, Case Western Reserve University

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024
Article
Matthew Lunning, DO, FACP

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023
Podcast
FDA

NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML

April 30th 2024
Article
Sundar Jagannath, MBBS, of Mount Sinai

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

April 25th 2024
Article